Obstructive sleep apnoea and cardiovascular complications: Perception versus knowledge

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 12, 2012, Pages 995-1003

  Thomas, Joi J ^a   Ren, Jun ^a  

^a UNIVERSITY OF WYOMING COLLEGE OF HEALTH SCIENCES   (United States)

Author keywords

Cardiovascular disease; Obstructive sleep apnoea; Risk factor

Indexed keywords

AGE DISTRIBUTION; APNEA HYPOPNEA INDEX; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRINKING; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INFLAMMATION; KNOWLEDGE; LIVER METABOLISM; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PERCEPTION; PREVALENCE; RACE; REVIEW; SEX RATIO; SLEEP DISORDERED BREATHING; SMOKING; SYMPATHETIC FUNCTION;

CARDIOVASCULAR DISEASE; OBSTRUCTIVE SLEEP APNOEA; RISK FACTOR;

CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; FATTY LIVER; HUMANS; OXIDATIVE STRESS; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE; SYMPATHETIC NERVOUS SYSTEM;

EID: 84870278907     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12024     Document Type: Review

References (100)

1. Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics: 2011 update. Circulation 2011; 123: e18-209.
2. Narkiewicz K, van de Borne PJH, Cooley RL, Dyken ME, Somers VK. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998; 98: 772-6.
3. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J. Clin. Invest. 1995; 96: 1897-904.
4. Butt M, Dwivedi G, Khair O, Lip GYH. Obstructive sleep apnea and cardiovascular disease. Int. J. Cardiol. 2010; 139: 7-16.
5. Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. Semin. Thromb. Hemost. 2011; 37: 280-97.
6. Shahar E, Whitney CW, Redline S et al. Sleep-disordered breathing and cardiovascular disease: Cross-sectional results of the sleep heart health study. Am. J. Respir. Crit. Care Med. 2001; 163: 19-25.
7. Hudgel DW. Mechanisms of obstructive sleep apnea. Chest 1992; 101: 541-9.
8. Pinto JM, Garpestad E, Weiss JW, Bergau DM, Kirby DA. Hemodynamic changes associated with obstructive sleep apnea followed by arousal in a porcine model. J. Appl. Physiol. 1993; 75: 1439-43.
9. Shamsuzzaman ASM, Gersh BJ, Somers VK. Obstructive sleep apnea: Implications for cardiac and vascular disease. JAMA 2003; 290: 1906-14.
10. Young T. Epidemiology of obstructive sleep apnea: A population health perspective. Am. J. Respir. Crit. Care Med. 2002; 165: 1217-39.
11. Guilleminault C, Stoohs R, Clerk A, Cetel M, Maistros P. A cause of excessive daytime sleepiness. The upper airway resistance syndrome. Chest 1993; 104: 781-7.
12. Jean-Louis G, Brown CD, Zizi F et al. Cardiovascular disease risk reduction with sleep apnea treatment. Expert Rev. Cardiovasc. Ther. 2010; 8: 995-1005.
13. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am. J. Respir. Crit. Care Med. 2002; 165: 934-9.
14. Kent BD, Ryan S, McNicholas WT. Obstructive sleep apnea and inflammation: Relationship to cardiovascular co-morbidity. Respir. Physiol. Neurobiol. 2011; 178: 475-81.
15. Lavie L, Dyugovskaya L, Golan-Shany O, Lavie P. Heat-shock protein 70: Expression in monocytes of patients with sleep apnoea and association with oxidative stress and tumour necrosis factor-alpha. J. Sleep Res. 2010; 19: 139-47.
16. Mohsenin V, Urbano F. Circulating antiangiogenic proteins in obstructive sleep apnea and hypertension. Respir. Med. 2011; 105: 801-7.
17. Ip MS, Tse HF, Lam B, Tsang KW, Lam WK. Endothelial function in obstructive sleep apnea and response to treatment. Am. J. Respir. Crit. Care Med. 2004; 169: 348-53.
18. Chung S, Yoon IY, Lee CH, Kim JW. The association of nocturnal hypoxemia with arterial stiffness and endothelial dysfunction in male patients with obstructive sleep apnea syndrome. Respiration 2010; 79: 363-9.
19. El-Solh AA, Mador MJ, Sikka P, Dhillon RS, Amsterdam D, Grant BJB. Adhesion molecules in patients with coronary artery disease and moderate-to-severe obstructive sleep apnea. Chest 2002; 121: 1541-7.
20. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J. Clin. Endocrinol. Metab. 1997; 82: 1313-6.
21. Mehra R, Storfer-Isser A, Kirchner HL et al. Soluble interleukin 6 receptor: A novel marker of moderate to severe sleep-related breathing disorder. Arch. Intern. Med. 2006; 166: 1725-31.
22. Del Rio R, Moya EA, Iturriaga R. Differential expression of pro-inflammatory cytokines, endothelin-1 and nitric oxide synthases in the rat carotid body exposed to intermittent hypoxia. Brain Res. 2011; 1395: 74-85.
23. Das AM, Khayat R. Hypertension in obstructive sleep apnea: Risk and therapy. Expert Rev. Cardiovasc. Ther. 2009; 7: 619-26.
24. Devulapally K, Pongonis R Jr, Khayat R. OSA: The new cardiovascular disease: Part II: Overview of cardiovascular diseases associated with obstructive sleep apnea. Heart Fail. Rev. 2009; 14: 155-64.
25. Budhiraja R, Budhiraja P, Quan SF. Sleep-disordered breathing and cardiovascular disorders. Respir. Care 2010; 55: 1322-32.
26. Palta M, Skatrud J, Young T, Peppard PE. Prospective study of the association between sleep-disordered breathing and hypertension. N. Engl. J. Med. 2000; 342: 1378-84.
27. O'Connor GT, Caffo B, Newman AB et al. Prospective study of sleep-disordered breathing and hypertension: The Sleep Heart Health Study. Am. J. Respir. Crit. Care Med. 2009; 179: 1159-64.
28. Peppard PE. Is obstructive sleep apnea a risk factor for hypertension? Differences between the Wisconsin Sleep Cohort and the Sleep Heart Health Study J. Clin. Sleep Med. 2009; 5: 404-5.
29. Drager LF, Genta PR, Pedrosa RP et al. Characteristics and predictors of obstructive sleep apnea in patients with systemic hypertension. Am. J. Cardiol. 2010; 105: 1135-9.
30. Thomopoulos C, Tsioufis C, Dimitriadis K et al. Obstructive sleep apnoea syndrome is associated with enhanced sub-clinical inflammation and asymmetric dimethyl-arginine levels in hypertensives. J. Hum. Hypertens. 2009; 23: 65-7.
31. Vgontzas AN, Zoumakis E, Bixler EO et al. Selective effects of CPAP on sleep apnoea-associated manifestations. Eur. J. Clin. Invest. 2008; 38: 585-95.
32. Yue HJ, Mills PJ, Ancoli-Israel S, Loredo JS, Ziegler MG, Dimsdale JE. The roles of TNF-alpha and the soluble TNF receptor I on sleep architecture in OSA. Sleep Breath. 2009; 13: 263-9.
33. Tamaki S, Yamauchi M, Fukuoka A et al. Production of inflammatory mediators by monocytes in patients with obstructive sleep apnea syndrome. Intern. Med. 2009; 48: 1255-62.
34. Navarro-Gonzalez JF, Mora C, Muros M, Jarque A, Herrera H, Garcia J. Association of tumor necrosis factor-alpha with early target organ damage in newly diagnosed patients with essential hypertension. J. Hypertens. 2008; 26: 2168-75.
35. Li N-F, Yao X-G, Zhu J et al. Higher levels of plasma TNF-alpha and neuropeptide Y in hypertensive patients with obstructive sleep apnea syndrome. Clin. Exp. Hypertens. 2010; 32: 54-60.
36. Tsioufis C, Kordalis A, Flessas D et al. Pathophysiology of resistant hypertension: The role of sympathetic nervous system. Int. J. Hypertens. 2011; 2011: 642416.
37. Drager LF, Ueno LM, Lessa PS, Negrao CE, Lorenzi-Filho G, Krieger EM. Sleep-related changes in hemodynamic and autonomic regulation in human hypertension. J. Hypertens. 2009; 27: 1655-63.
38. O'Driscoll DM, Horne RSC, Davey MJ et al. Increased sympathetic activity in children with obstructive sleep apnea: Cardiovascular implications. Sleep Med. 2011; 12: 483-8.
39. Duran-Cantolla J, Aizpuru F, Montserrat JM et al. Continuous positive airway pressure as treatment for systemic hypertension in people with obstructive sleep apnoea: Randomised controlled trial. BMJ 2010; 341: c5991.
40. Lozano L, Tovar JL, Sampol G et al. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: A randomized, controlled trial. J. Hypertens. 2010; 28: 2161-8.
41. Mehra R, Benjamin EJ, Shahar E et al. Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study. Am. J. Respir. Crit. Care Med. 2006; 173: 910-16.
42. Gami AS, Hodge DO, Herges RM et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J. Am. Coll. Cardiol. 2007; 49: 565-71.
43. Gami AS, Somers VK. Implications of obstructive sleep apnea for atrial fibrillation and sudden cardiac death. J. Cardiovasc. Electrophysiol. 2008; 19: 997-1003.
44. Dursunoglu D, Dursunoglu N, Evrengul H et al. Impact of obstructive sleep apnoea on left ventricular mass and global function. Eur. Respir. J. 2005; 26: 283-8.
45. Cloward TV, Walker JM, Farney RJ, Anderson JL. Left ventricular hypertrophy is a common echocardiographic abnormality in severe obstructive sleep apnea and reverses with nasal continuous positive airway pressure. Chest 2003; 124: 594-601.
46. Shivalkar B, Van De Heyning C, Kerremans M et al. Obstructive sleep apnea syndrome: More insights on structural and functional cardiac alterations, and the effects of treatment with continuous positive airway pressure. J. Am. Coll. Cardiol. 2006; 47: 1433-9.
47. Mooe T, Gullsby S, Rabben T, Eriksson P. Sleep-disordered breathing: A novel predictor of atrial fibrillation after coronary artery bypass surgery. Coron. Artery Dis. 1996; 7: 475-8.
48. Sorajja D, Gami AS, Somers VK, Behrenbeck TR, Garcia-Touchard A, Lopez-Jimenez F. Independent association between obstructive sleep apnea and subclinical coronary artery disease. Chest 2008; 133: 927-33.
49. Chami HA, Resnick HE, Quan SF, Gottlieb DJ. Association of incident cardiovascular disease with progression of sleep-disordered breathing. Circulation 2011; 123: 1280-6.
50. Punjabi NM, Caffo BS, Goodwin JL et al. Sleep-disordered breathing and mortality: A prospective cohort study. PLoS Med. 2009; 6: 1-9.
51. Ma S, Mifflin SW, Cunningham JT, Morilak DA. Chronic intermittent hypoxia sensitizes acute hypothalamic-pituitary-adrenal stress reactivity and Fos induction in the rat locus coeruleus in response to subsequent immobilization stress. Neuroscience 2008; 154: 1639-47.
52. Nakashima H, Katayama T, Takagi C et al. Obstructive sleep apnoea inhibits the recovery of left ventricular function in patients with acute myocardial infarction. Eur. Heart J. 2006; 27: 2317-22.
53. Karkoulias K, Lykouras D, Sampsonas F et al. The role of endothelin-1 in obstructive sleep apnea syndrome and pulmonary arterial hypertension: Pathogenesis and endothelin-1 antagonists. Curr. Med. Chem. 2010; 17: 1059-66.
54. Drager LF, Bortolotto LA, Figueiredo AC, Kreiger EM, Lorenzi GF. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am. J. Respir. Crit. Care Med. 2007; 176: 706-12.
55. Dorkova Z, Petrasova D, Molcanyiova A, Popovnakova M, Tkacova R. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest 2008; 134: 686-92.
56. Kohler M, Ayers L, Pepperell JC et al. Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: A randomised controlled trial. Thorax 2009; 64: 67-73.
57. Julien C, Sam B, Patrick L. Vascular reactivity to norepinephrine and acetylcholine after chronic intermittent hypoxia in mice. Respir. Physiol. Neurobiol. 2003; 139: 21-32.
58. Kasai T, Bradley TD. Obstructive sleep apnea and heart failure: Pathophysiologic and therapeutic implications. J. Am. Coll. Cardiol. 2011; 57: 119-27.
59. Gottlieb DJ, Yenokyan G, Newman AB et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: The Sleep Heart Health Study. Circulation 2010; 122: 352-60.
60. Kahwash R, Kikta D, Khayat R. Recognition and management of sleep-disordered breathing in chronic heart failure. Curr. Heart Fail. Rep. 2011; 8: 72-9.
61. Brisco MA, Goldberg LR. Sleep apnea in congestive heart failure. Curr. Heart Fail. Rep. 2010; 7: 175-84.
62. Lee C-H, Khoo S-M, Chan MY et al. Severe obstructive sleep apnea and outcomes following myocardial infarction. J. Clin. Sleep Med. 2011; 7: 616-21.
63. Wang H, Parker JD, Newton GE et al. Influence of obstructive sleep apnea on mortality in patients with heart failure. J. Am. Coll. Cardiol. 2007; 49: 1625-31.
64. Egea CJ, Aizpuru F, Pinto JA et al. Cardiac function after CPAP therapy in patients with chronic heart failure and sleep apnea: A multicenter study. Sleep Med. 2008; 9: 660-6.
65. Khayat RN, Abraham WT, Patt B, Roy M, Hua K, Jarjoura D. Cardiac effects of continuous and bilevel positive airway pressure for patients with heart failure and obstructive sleep apnea: A pilot study. Chest 2008; 134: 1162-8.
66. Khayat R, Patt B, Hayes D Jr. Obstructive sleep apnea: The new cardiovascular disease. Part I. Obstructive sleep apnea and the pathogenesis of vascular disease. Heart Fail. Rev. 2009; 14: 143-53.
67. Dematteis M, Godin-Ribuot D, Arnaud C et al. Cardiovascular consequences of sleep-disordered breathing: Contribution of animal models to understanding of the human disease. ILAR J. 2009; 50: 262-81.
68. Fletcher E. Sympathetic over activity in the etiology of hypertension of obstructive sleep apnea. Sleep 2003; 23: 15-19.
69. McArdle N, Hillman D, Beilin L, Watts G. Metabolic risk factors for vascular disease in obstructive sleep apnea: A matched controlled study. Am. J. Respir. Crit. Care Med. 2007; 175: 190-5.
70. Carlson JT, Hedner J, Elam M, Ejnell H, Sellgren J, Wallin B. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest 1993; 103: 1763-8.
71. Lavie L. Obstructive sleep apnoea syndrome: An oxidative stress disorder. Sleep Med. Rev. 2003; 7: 35-51.
72. Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005; 112: 2660-7.
73. Greenberg HYeX, Wilson D, Htoo AK, Henderson T, Liu SF. Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem. Biophys. Res. Commun. 2006; 343: 591-6.
74. Quercioli A, Mach F, Montecucco F. Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS). Sleep Breath. 2010; 14: 261-9.
75. Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract. Res. Clin. Gastroenterol. 2010; 24: 695-708.
76. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog. Lipid Res. 2009; 48: 1-26.
77. Moore JB. Non-alcoholic fatty liver disease: The hepatic consequence of obesity and the metabolic syndrome. Proc. Nutr. Soc. 2010; 69: 211-20.
78. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig. Liver Dis. 2010; 42: 320-30.
79. Ahmed MH. Obstructive sleep apnea syndrome and fatty liver: Association or causal link? World J. Gastroenterol. 2010; 16: 4243.
80. Tian JL, Zhang Y, Chen BY. Sleep apnea hypopnea syndrome and liver injury. Chin. Med. J. 2010; 123: 89-94.
81. Daltro C, Cotrim HP, Alves E et al. Nonalcoholic fatty liver disease associated with obstructive sleep apnea: Just a coincidence? Obes. Surg. 2010; 20: 1536-43.
82. Li J, Grigoryev DN, YeSQ et al. Chronic intermittent hypoxia upregulates genes of lipid biosynthesis in obese mice. J. Appl. Physiol. 2005; 99: 1643-8.
83. Savransky V, Bevans S, Nanayakkara A et al. Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am. J. Physiol. Gastrointest. Liver Physiol. 2007; 293: G871-7.
84. Jun J, Savransky V, Nanayakkara A et al. Intermittent hypoxia has organ-specific effects on oxidative stress. Am. J. Physiol. Regul. Intergr. Comp. Physiol. 2008; 295: R1274-81.
85. Norman D, Bardwell WA, Arosemena F et al. Serum aminotransferase levels are associated with markes of hypoxia in patients with obstructive sleep apnea. Sleep 2008; 31: 121-6.
86. Mishra P, Nugent C, Afendy A et al. Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int. 2008; 28: 1080-6.
87. Aron-Wisnewsky J, Minville C, Tordjman J et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J. Hepatol. 2012; 56: 225-33.
88. Singh H, Pollock R, Uhanova J, Kryger M, Hawkins K, Minuk GY. Symptoms of obstructive sleep apnea in patients with nonalcoholic fatty liver disease. Dig. Dis. Sci. 2005; 50: 2338-43.
89. Kohler M, Pepperell JC, Davies RJ, Stradling JR. Continuous positive airway pressure and liver enzymes in obstructive sleep apnoea: Data from a randomized controlled trial. Respiration 2009; 78: 141-6.
90. Shpirer I, Copel L, Broide E, Elizur A. Continuous positive airway pressure improves sleep apnea associated fatty liver. Lung 2010; 188: 301-7.
91. Bugianesi E, Gastaldelli A, Vanni E et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: Sites and mechanisms. Diabetologia 2005; 48: 634-42.
92. Barcelo A, Pierola J, de la Pena M et al. Free fatty acids and the metabolic syndrome in patients with obstructive sleep apnoea. Eur. Respir. J. 2011; 37: 1418-23.
93. Volgin DV, Kubin L. Chronic intermittent hypoxia alters hypothalamic transcription of genes involved in metabolic regulation. Auton. Neurosci. 2006; 127: 93-9.
94. Lin Q-C, Zhang X-B, Chen G-P, Huang D-Y, Din H-B, Tang A-Z. Obstructive sleep apnea syndrome is associated with some components of metabolic syndrome in nonobese adults. Sleep Breath. 2012; 16: 571-8.
95. Sharma SK, Agrawal S, Damodaran D et al. CPAP for the metabolic syndrome in patients with obstructive sleep apnea. N. Engl. J. Med. 2011; 365: 2277-86.
96. Donnelly KL. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 2005; 115: 1343-51.
97. Savransky V, Nanayakkara A, Li J et al. Chronic intermittent hypoxia induces atherosclerosis. Am. J. Respir. Crit. Care Med. 2007; 175: 1290-7.
98. Drager LF, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: An emerging risk factor for atherosclerosis. Chest 2011; 140: 534-42.
99. Kohler M, Stradling JR. Mechanisms of vascular damage in obstructive sleep apnea. Nat. Rev. Cardiol. 2010; 7: 677-85.
100. Musso G, Olivetti C, Cassader M, Gambino R. Obstructive sleep apnea-hypopnea syndrome and nonalcoholic fatty liver disease: Emerging evidence and mechanisms. Semin. Liver Dis. 2012; 32: 49-64.